NEW YORK, March 07, 2016 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (Nasdaq:TGTX) today announced its participation at two upcoming investment conferences. Michael S. Weiss, the Company's Executive Chairman and Interim Chief Executive Officer, is scheduled to present tomorrow Tuesday, March 8, 2016 at 11:35am ET, at the Raymond James & Associates' 37th Annual Institutional Investors Conference, being held at the JW Marriott Grande Lakes in Orlando, Florida. Michael Weiss is also scheduled to present on Wednesday, March 9, 2016 at 9:20am ET at the
Cowen and Company 36th Annual Health Care Conference, being held at the Marriott Copley Place.
The presentations will be webcast live, and will be available on the Events page, located within the Investors & Media section, of the Company's website at www.tgtherapeutics.com.
ABOUT TG THERAPEUTICS, INC.
TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Currently, the Company is developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that
targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. TG Therapeutics is also developing TGR-1202, an orally available PI3K delta inhibitor. The delta isoform of PI3K is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of B-lymphocytes. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies. The Company also has a pre-clinical program to develop IRAK4 inhibitors, as well as an antibody research program to develop anti-PD-L1 and anti-GITR antibodies. TG Therapeutics is headquartered in New York City.
TGTX - G
Jenna Bosco
Director- Investor Relations
TG Therapeutics, Inc.
Telephone: 212.554.4351
Email: ir@tgtxinc.com
Source:
TG Therapeutics, Inc.
News Provided by Acquire Media
